[
  {
    "ts": null,
    "headline": "Is Bristol-Myers Squibb a Value Opportunity After 5.1% Rebound and DCF Outlook?",
    "summary": "If you are wondering whether Bristol-Myers Squibb is quietly becoming a value opportunity or just a classic value trap, you are in the right place to unpack what the current share price is really telling us. The stock has edged up about 5.1% over the last month after a softer year to date, with the price still down 9.8% since January and around 4.5% lower over the past year. This suggests sentiment is shifting but not yet fully recovered. Recently, investors have been focused on...",
    "url": "https://finnhub.io/api/news?id=9fc7e9d44aa78b02948e4c981405e7d44b832eac83d9899fdb69457fd4018011",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765563121,
      "headline": "Is Bristol-Myers Squibb a Value Opportunity After 5.1% Rebound and DCF Outlook?",
      "id": 137770452,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "If you are wondering whether Bristol-Myers Squibb is quietly becoming a value opportunity or just a classic value trap, you are in the right place to unpack what the current share price is really telling us. The stock has edged up about 5.1% over the last month after a softer year to date, with the price still down 9.8% since January and around 4.5% lower over the past year. This suggests sentiment is shifting but not yet fully recovered. Recently, investors have been focused on...",
      "url": "https://finnhub.io/api/news?id=9fc7e9d44aa78b02948e4c981405e7d44b832eac83d9899fdb69457fd4018011"
    }
  },
  {
    "ts": null,
    "headline": "Why Bristol-Myers Squibb (BMY) Stock Is Up Today",
    "summary": "Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) jumped 2.6% in the afternoon session after an analyst at Guggenheim upgraded the company's stock from \"Neutral\" to \"Buy\" and set a new price target of $62.",
    "url": "https://finnhub.io/api/news?id=59e7e2d8cffbc3b1b103818c8ba2eabb5d75ac2330693ebe00c16690c3e60ffd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765561550,
      "headline": "Why Bristol-Myers Squibb (BMY) Stock Is Up Today",
      "id": 137770454,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) jumped 2.6% in the afternoon session after an analyst at Guggenheim upgraded the company's stock from \"Neutral\" to \"Buy\" and set a new price target of $62.",
      "url": "https://finnhub.io/api/news?id=59e7e2d8cffbc3b1b103818c8ba2eabb5d75ac2330693ebe00c16690c3e60ffd"
    }
  },
  {
    "ts": null,
    "headline": "Why Arcus Biosciences Just Reversed Its 287% Eight-Month Winning Streak",
    "summary": "Arcus Biosciences stock plunged Friday, reversing a nearly 300% gain, after its Gilead Sciences-partnered cancer regimen failed.",
    "url": "https://finnhub.io/api/news?id=d957fc48a5eb959e96b2cb823a54cb45eeb47709d391408d008694ed12aecb7b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765560949,
      "headline": "Why Arcus Biosciences Just Reversed Its 287% Eight-Month Winning Streak",
      "id": 137769492,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Arcus Biosciences stock plunged Friday, reversing a nearly 300% gain, after its Gilead Sciences-partnered cancer regimen failed.",
      "url": "https://finnhub.io/api/news?id=d957fc48a5eb959e96b2cb823a54cb45eeb47709d391408d008694ed12aecb7b"
    }
  },
  {
    "ts": null,
    "headline": "Can Opdivo's Label Expansions Help Bristol Myers Sustain Its Momentum?",
    "summary": "BMY gets a priority FDA review for Opdivo's use in previously untreated advanced Hodgkin lymphoma, reinforcing its oncology momentum.",
    "url": "https://finnhub.io/api/news?id=80d50ab2d8fac31f908832ea3f45722c7ad31bec6a44bd9ae59e296273fe16e4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765553700,
      "headline": "Can Opdivo's Label Expansions Help Bristol Myers Sustain Its Momentum?",
      "id": 137769422,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "BMY gets a priority FDA review for Opdivo's use in previously untreated advanced Hodgkin lymphoma, reinforcing its oncology momentum.",
      "url": "https://finnhub.io/api/news?id=80d50ab2d8fac31f908832ea3f45722c7ad31bec6a44bd9ae59e296273fe16e4"
    }
  },
  {
    "ts": null,
    "headline": "The Best Turnaround Stock to Invest $1,000 in Right Now",
    "summary": "Pfizer and Bristol Myers Squibb are deeply out-of-favor drugmakers, but one could be the better turnaround candidate if you think long term.",
    "url": "https://finnhub.io/api/news?id=1b76b1faadd3a83833ecc198afa9566f376e40ff8ac2930ead2908e58620301d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765553700,
      "headline": "The Best Turnaround Stock to Invest $1,000 in Right Now",
      "id": 137769498,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Pfizer and Bristol Myers Squibb are deeply out-of-favor drugmakers, but one could be the better turnaround candidate if you think long term.",
      "url": "https://finnhub.io/api/news?id=1b76b1faadd3a83833ecc198afa9566f376e40ff8ac2930ead2908e58620301d"
    }
  },
  {
    "ts": null,
    "headline": "Can MRK's New Drugs & Pipeline Help Navigate the Looming Keytruda LOE?",
    "summary": "Merck leans on a fast-growing pipeline and new product launches to aid long-term growth as Keytruda's 2028 LOE nears.",
    "url": "https://finnhub.io/api/news?id=e23bff1d294d5bd253d567c0746d26bc388f53ce2269d061f254a86ffd70b673",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765551780,
      "headline": "Can MRK's New Drugs & Pipeline Help Navigate the Looming Keytruda LOE?",
      "id": 137769425,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Merck leans on a fast-growing pipeline and new product launches to aid long-term growth as Keytruda's 2028 LOE nears.",
      "url": "https://finnhub.io/api/news?id=e23bff1d294d5bd253d567c0746d26bc388f53ce2269d061f254a86ffd70b673"
    }
  },
  {
    "ts": null,
    "headline": "Roblox downgraded, Lululemon upgraded: Wall Street's top analyst calls",
    "summary": "Roblox downgraded, Lululemon upgraded: Wall Street's top analyst calls",
    "url": "https://finnhub.io/api/news?id=210b3ea93e519da8ba810002ecfdca31cba70e217505805a0f714ee0c73d79a0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765550142,
      "headline": "Roblox downgraded, Lululemon upgraded: Wall Street's top analyst calls",
      "id": 137769385,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Roblox downgraded, Lululemon upgraded: Wall Street's top analyst calls",
      "url": "https://finnhub.io/api/news?id=210b3ea93e519da8ba810002ecfdca31cba70e217505805a0f714ee0c73d79a0"
    }
  },
  {
    "ts": null,
    "headline": "Here Are Friday’s Top Wall Street Analyst Research Calls: Bristol-Myers Squibb, Citigroup, Lululemon Athletica, PayPal, Roblox, Soundhound AI, and More",
    "summary": "Pre-Market Stock Futures: The futures are trading mixed as we get set to close out a wild and woolly week that saw a touch of just about everything. The Federal Reserve, as expected, cut rates again and indicated that another cut could come in 2026. Oracle Corp. (NASDAQ: ORCL), which has been on fire this ... Here Are Friday’s Top Wall Street Analyst Research Calls: Bristol-Myers Squibb, Citigroup, Lululemon Athletica, PayPal, Roblox, Soundhound AI, and More",
    "url": "https://finnhub.io/api/news?id=483b2c13d9ebe0a28608ee77e03d6df234d870269498f1c6c1097f4268857dfd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765548805,
      "headline": "Here Are Friday’s Top Wall Street Analyst Research Calls: Bristol-Myers Squibb, Citigroup, Lululemon Athletica, PayPal, Roblox, Soundhound AI, and More",
      "id": 137769530,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Pre-Market Stock Futures: The futures are trading mixed as we get set to close out a wild and woolly week that saw a touch of just about everything. The Federal Reserve, as expected, cut rates again and indicated that another cut could come in 2026. Oracle Corp. (NASDAQ: ORCL), which has been on fire this ... Here Are Friday’s Top Wall Street Analyst Research Calls: Bristol-Myers Squibb, Citigroup, Lululemon Athletica, PayPal, Roblox, Soundhound AI, and More",
      "url": "https://finnhub.io/api/news?id=483b2c13d9ebe0a28608ee77e03d6df234d870269498f1c6c1097f4268857dfd"
    }
  },
  {
    "ts": null,
    "headline": "3 Top Dividend Stocks to Maximize Your Retirement Income",
    "summary": "The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?",
    "url": "https://finnhub.io/api/news?id=554782490fb3c48be29ad58a1b769f6016de8753ee20668705e86c74470f6e82",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765548602,
      "headline": "3 Top Dividend Stocks to Maximize Your Retirement Income",
      "id": 137769531,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?",
      "url": "https://finnhub.io/api/news?id=554782490fb3c48be29ad58a1b769f6016de8753ee20668705e86c74470f6e82"
    }
  },
  {
    "ts": null,
    "headline": "These Stocks Are Moving the Most Today: Broadcom, Oracle, Lululemon, Costco, Netskope, and More",
    "summary": "Broadcom falls after reporting earnings, Oracle extends losses, and Lululemon beats analysts’ estimates for third-quarter earnings and revenue.",
    "url": "https://finnhub.io/api/news?id=f713485a6c78ead1b469266f2a542a7ab20ab4677e1aa87ce9911ab9f0939f30",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765540320,
      "headline": "These Stocks Are Moving the Most Today: Broadcom, Oracle, Lululemon, Costco, Netskope, and More",
      "id": 137766756,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Broadcom falls after reporting earnings, Oracle extends losses, and Lululemon beats analysts’ estimates for third-quarter earnings and revenue.",
      "url": "https://finnhub.io/api/news?id=f713485a6c78ead1b469266f2a542a7ab20ab4677e1aa87ce9911ab9f0939f30"
    }
  },
  {
    "ts": null,
    "headline": "How the Narrative Surrounding Bristol Myers Squibb Is Shifting After Recent Sector and Policy Updates",
    "summary": "Bristol-Myers Squibb has seen its fair value estimate nudged slightly higher to about $53.55 per share, even as analysts bake in a marginally higher discount rate of roughly 6.96% and a deeper projected revenue decline of around -5.34%. This combination reflects cautious recognition that sector wide underperformance and a potentially less punitive policy backdrop could support a gradual rerating, even while expectations for top line growth remain subdued. Stay tuned to see how investors can...",
    "url": "https://finnhub.io/api/news?id=7e782cbcf1ca00d7aa1f056d01de2c67b13570545fc2c61cd3e441fde743eb0b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765530736,
      "headline": "How the Narrative Surrounding Bristol Myers Squibb Is Shifting After Recent Sector and Policy Updates",
      "id": 137767074,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb has seen its fair value estimate nudged slightly higher to about $53.55 per share, even as analysts bake in a marginally higher discount rate of roughly 6.96% and a deeper projected revenue decline of around -5.34%. This combination reflects cautious recognition that sector wide underperformance and a potentially less punitive policy backdrop could support a gradual rerating, even while expectations for top line growth remain subdued. Stay tuned to see how investors can...",
      "url": "https://finnhub.io/api/news?id=7e782cbcf1ca00d7aa1f056d01de2c67b13570545fc2c61cd3e441fde743eb0b"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer's top 10 things to watch in the stock market Friday",
    "summary": "Investors continue their rotation out of tech and into value areas of the market as the Dow heads for a higher open while the Nasdaq lags.",
    "url": "https://finnhub.io/api/news?id=a1c6918b8542bd9eb4150f6f40f0cd54886aae58a1973ae457b0695727c38cb7",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765530494,
      "headline": "Jim Cramer's top 10 things to watch in the stock market Friday",
      "id": 137768818,
      "image": "https://image.cnbcfm.com/api/v1/image/108238411-17652128912025-12-08t165355z_549336374_rc2dciacdm2q_rtrmadp_0_usa-stocks.jpeg?v=1765213081&w=1920&h=1080",
      "related": "BMY",
      "source": "CNBC",
      "summary": "Investors continue their rotation out of tech and into value areas of the market as the Dow heads for a higher open while the Nasdaq lags. ",
      "url": "https://finnhub.io/api/news?id=a1c6918b8542bd9eb4150f6f40f0cd54886aae58a1973ae457b0695727c38cb7"
    }
  }
]